Pilot study on silibinin as a possible therapeutic agent for mildly ill COVID-19 patients
Phase 1
- Conditions
- antiviral effect of silibinin against SARS-CoV2Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- EUCTR2020-005580-32-AT
- Lead Sponsor
- Medical University of Vienna
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Patients with mild COVID-19 disease without the need for assisted ventilation
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 15
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 15
Exclusion Criteria
Need for assisted ventilation
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: antiviral treatment of mild COVID-19 disease with silibinin by examining viral elimination kinetics;Secondary Objective: Not applicable;Primary end point(s): Viral decay on day 10 or undetectable virus by PCR at any time before day 10;Timepoint(s) of evaluation of this end point: day10
- Secondary Outcome Measures
Name Time Method Secondary end point(s): day10;Timepoint(s) of evaluation of this end point: day 10